tetano
Editor, Senior Moderator
Dig Dis Sci
. 2023 Oct 21.
doi: 10.1007/s10620-023-08105-x. Online ahead of print. Mortality Increased Among Hospitalized Patients with Cirrhosis Before and Following Different Waves of the COVID-19 Pandemic
Patrick A Twohig[SUP] 1 [/SUP], Kyle Scholten[SUP] 2 [/SUP], Makayla Schissel[SUP] 3 [/SUP], Kevin Brittan[SUP] 2 [/SUP], Jason Barbaretta[SUP] 2 [/SUP], Kaeli Samson[SUP] 3 [/SUP], Lynette Smith[SUP] 3 [/SUP], Mark Mailliard[SUP] 4 [/SUP], Thoetchai Bee Peeraphatdit[SUP] 4 [/SUP]
Affiliations
Background: The Coronavirus disease 2019 (COVID-19) pandemic disrupted patient care and worsened the morbidity and mortality of some chronic diseases. The impact of the COVID-19 pandemic on hospitalizations and outcomes in patients with cirrhosis both before and during different time periods of the pandemic has not been evaluated.
Aims: Describe characteristics of hospitalized patients with cirrhosis and evaluate inpatient mortality and 30-day readmission before and after the start of the COVID-19 pandemic.
Methods: Retrospective single-center cohort study of all hospitalized patients with cirrhosis from 2018 to 2022. Time periods within the COVID-19 pandemic were defined using reference data from the World Health Organization and Centers for Disease Control. Adjusted odds ratios from logistic regression were used to assess differences between periods.
Results: 33,926 unique hospitalizations were identified. Most patients were over age 60 years across all time periods of the pandemic. More Hispanic patients were hospitalized during COVID-19 than before COVID-19. Medicare and Medicaid are utilized less frequently during COVID-19 than before COVID-19. After controlling for age and gender, inpatient mortality was significantly higher during all COVID-19 periods except Omicron compared to before COVID-19. The odds of experiencing a 30-day readmission were 1.2 times higher in the pre-vaccination period compared to the pre-COVID-19 period.
Conclusion: Inpatient mortality among patients with cirrhosis has increased during the COVID-19 pandemic compared to before COVID-19. Although COVID-19 infection may have had a small direct pathologic effect on the natural history of cirrhotic liver disease, it is more likely that other factors are impacting this population.
Keywords: COVID-19; Cirrhosis; Hospitalization; Mortality; Readmission.
. 2023 Oct 21.
doi: 10.1007/s10620-023-08105-x. Online ahead of print. Mortality Increased Among Hospitalized Patients with Cirrhosis Before and Following Different Waves of the COVID-19 Pandemic
Patrick A Twohig[SUP] 1 [/SUP], Kyle Scholten[SUP] 2 [/SUP], Makayla Schissel[SUP] 3 [/SUP], Kevin Brittan[SUP] 2 [/SUP], Jason Barbaretta[SUP] 2 [/SUP], Kaeli Samson[SUP] 3 [/SUP], Lynette Smith[SUP] 3 [/SUP], Mark Mailliard[SUP] 4 [/SUP], Thoetchai Bee Peeraphatdit[SUP] 4 [/SUP]
Affiliations
- PMID: 37864739
- DOI: 10.1007/s10620-023-08105-x
Background: The Coronavirus disease 2019 (COVID-19) pandemic disrupted patient care and worsened the morbidity and mortality of some chronic diseases. The impact of the COVID-19 pandemic on hospitalizations and outcomes in patients with cirrhosis both before and during different time periods of the pandemic has not been evaluated.
Aims: Describe characteristics of hospitalized patients with cirrhosis and evaluate inpatient mortality and 30-day readmission before and after the start of the COVID-19 pandemic.
Methods: Retrospective single-center cohort study of all hospitalized patients with cirrhosis from 2018 to 2022. Time periods within the COVID-19 pandemic were defined using reference data from the World Health Organization and Centers for Disease Control. Adjusted odds ratios from logistic regression were used to assess differences between periods.
Results: 33,926 unique hospitalizations were identified. Most patients were over age 60 years across all time periods of the pandemic. More Hispanic patients were hospitalized during COVID-19 than before COVID-19. Medicare and Medicaid are utilized less frequently during COVID-19 than before COVID-19. After controlling for age and gender, inpatient mortality was significantly higher during all COVID-19 periods except Omicron compared to before COVID-19. The odds of experiencing a 30-day readmission were 1.2 times higher in the pre-vaccination period compared to the pre-COVID-19 period.
Conclusion: Inpatient mortality among patients with cirrhosis has increased during the COVID-19 pandemic compared to before COVID-19. Although COVID-19 infection may have had a small direct pathologic effect on the natural history of cirrhotic liver disease, it is more likely that other factors are impacting this population.
Keywords: COVID-19; Cirrhosis; Hospitalization; Mortality; Readmission.